Sixty-four eyes were prospectively investigated. Group 1 (22 central retinal vein occlusion (CRVO) and 16 branch retinal vein occlusion (BRVO)) was treated with Ozurdex alone, and group 2 (14 CRVO and ...
IRVINE, Calif.--(BUSINESS WIRE)--Allergan, Inc., (NYSE: AGN) announced today that the U.S. Food and Drug Administration (FDA) has approved OZURDEX® (dexamethasone intravitreal implant) 0.7 mg, a ...
Please provide your email address to receive an email when new articles are posted on . Intravitreal steroids have been widely used in the treatment of various ocular pathologies including macular ...
Purpose To report outcome of eyes with recalcitrant and naive eyes with diabetic macular edema (DME) treated with intravitreal dexamethasone implants (Ozurdex) injection. Methods Retrospective ...
A sustained-release dexamethasone device implanted during pars plana vitrectomy may be effective in pre-emptively reducing macular edema in patients with various underlying ocular diseases at risk for ...
Cost regulators for the NHS in England and Wales are backing routine use of Allergan’s Ozurdex and AbbVie’s Humira to treat non-infectious posterior uveitis, a form of preventable vision loss. Cost ...
OZURDEX (dexamethasone) intravitreal implant by Allergan The FDA has approved Ozurdex (dexamethasone intravitreal implant, from Allergan) for the treatment of non-infectious ocular inflammation, or ...
Ozurdex is a biocompatible implant licensed for the treatment of cystoid macular oedema (CMO) after retinal vein occlusions. We report a case of anterior vitreous displacement of Ozurdex, discussing ...
Biodegradable implant delivers extended-release corticosteroid dexamethasone via intravitreal injection. FDA cleared Allergan’s Ozurdex® 0.7 mg for noninfectious ocular inflammation, or uveitis, ...
OZURDEX (dexamethasone) intravitreal implant by Allergan Allergan's Ozurdex (dexamethasone intravitreal implant) has been approved by the FDA for the treatment of macular edema following branch ...
Dexamethasone implants appear to be the best treatment for persistent or recurrent macular edema that often occurs in patients with uveitis, findings from a new study show. The 12-week, multicenter, ...